Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate Safety and PK in Partial Onset Seizures
NCT02535091Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Aug 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in partial epilepsy, sponsored by SK Life Science, Inc. Primary endpoint: Treatment-Emergent Adverse Events up to 215 weeks. Started Aug 2016; status: completed.
02
Drugs
cenobamate
03
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT02535091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535091.